Get started
Author

Kamlesh Kumar Sankhala

Observed names: Kamlesh Sankhala, Sankhala, Kamlesh Kumar
Observed institution: Cedars-Sinai Medical Center
OpenAlex ID: A5128144305
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial
2026 · Hairong Xu, Xiaohui Niu, et al. · The Lancet · 10
Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan
2026 · Thomas E. Ichim, Nikola Markov, et al. · Journal of Translational Medicine · 2
PDF
Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma
2026 · Saarang Kashyap, Esha Sankhala, et al. · Frontiers in Oncology · 1
Additional file 1 of Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan
2026 · Ichim, Thomas E., Markov, Nikola, et al. · Figshare
Additional file 2 of Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan
2026 · Ichim, Thomas E., Markov, Nikola, et al. · Figshare
Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan
2026 · Ichim, Thomas E., Markov, Nikola, et al. · Figshare
Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.
2026 · Stephane Champiat, Luke Kuttschreuter, et al. · Journal of Clinical Oncology
PP01.118: Phase 1b/2 trial of BNT324/DB-1311 (B7H3 ADC) with Pumitamig (BNT327; PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC): BNT324-01 Trial in Progress
2026 · Adam Schoenfeld, Alexander Spira, et al. · Journal of Thoracic Oncology
Works count: 8
Citation count: 12
H-index: 1
I10-index: 1
Year
Topic
Type